Rohit Thummalapalli

10PUBLICATIONS
148CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 26, 2026
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

|Nov 20, 2025
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.

Rohit Thummalapalli, Salomon Tendler, Joanne F Chou

|Sep 24, 2025
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas.

Jessica S Ross, Rohit Thummalapalli, Kristine Lacuna

|Sep 16, 2025
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer.

Darren Cowzer, Madison Darmofal, Kenneth Seier

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

|Nov 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.

Samuel Rosner, Sydney Connor, Khaled Sanber

Pageof 2

Frequent Collaborators

4 joint publications

Charles M Rudin

3 joint publications

Mark M Awad

3 joint publications

Jinru Shia

3 joint publications

Adam J Schoenfeld